While these observations were made in a limited sample set, they align with our preclinical findings, supporting a potential tumor-progressive role of the ROR2-YAP/TEAD axis in patients with HER2-positive cancers characterized by trastuzumab resistance. This evidence concerns the gene ERBB2 and neoplasm.